NewsBenzingaReported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial Benzinga 2026.09.29 08:29 (GMT+0) Open on Benzinga Other news Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up Bank of New York Earnings Preview: What to Expect Oracle Bear Call Spread Could Net 20% in Under Two Months Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst Earnings Preview: What To Expect From Morgan Stanley's Report
Gate Ventures: US stocks rebound and oil prices retreat, institutional access narrative in crypto market heats up
Slim Jim Maker Conagra Brands Braces for First Quarter Sales Drop to $2.59B as Analysts Lower Forecast for CAG Stock - TipRanks.com
Micron Is in the ‘Best Cycle Anyone’ Has Ever Seen — MU Stock Is ‘in a Bubble,’ But Bulls Can Still Profit, Says Analyst
